Abstract
Levodopa-Carbidopa Intestinal Gel (LCIG) 16-h infusion offers superior symptomatic control than oral levodopa/carbidopa in patients with advanced Parkinson's disease (aPD); however, it requires percutaneous endoscopic gastrostomy tube placement. Foslevodopa/foscarbidopa is an investigational drug being developed for treatment of aPD providing 24-h therapeutic levels of levodopa following subcutaneous (SC) delivery. We characterize levodopa pharmacokinetics (PK) following foslevodopa/foscarbidopa SC infusion and LCIG jejunal infusion in healthy volunteers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
